Cingulate Inc (NASDAQ:CING) Short Interest Update

Cingulate Inc (NASDAQ:CINGGet Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 124,200 shares, an increase of 2,600.0% from the March 15th total of 4,600 shares. Based on an average trading volume of 267,300 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.7% of the shares of the stock are short sold.

Cingulate stock traded down $0.11 during midday trading on Tuesday, reaching $1.75. 31,503 shares of the company were exchanged, compared to its average volume of 167,000. The company’s 50-day moving average is $1.62. Cingulate has a 1 year low of $1.15 and a 1 year high of $5.15.

Cingulate (NASDAQ:CINGGet Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07.

In other Cingulate news, Director Peter J. Werth bought 27,000 shares of Cingulate stock in a transaction on Thursday, March 17th. The stock was bought at an average price of $1.79 per share, with a total value of $48,330.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders acquired 71,228 shares of company stock valued at $109,211.

An institutional investor recently bought a new position in Cingulate stock. Susquehanna International Group LLP purchased a new stake in Cingulate Inc (NASDAQ:CINGGet Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,338 shares of the company’s stock, valued at approximately $29,000. Susquehanna International Group LLP owned 0.09% of Cingulate at the end of the most recent reporting period. 23.03% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on the company. Laidlaw assumed coverage on Cingulate in a research note on Thursday, January 20th. They set a “buy” rating and a $8.50 price target for the company. Aegis began coverage on Cingulate in a research note on Tuesday, January 11th. They set a “buy” rating and a $9.00 price target for the company.

Cingulate Company Profile (Get Rating)

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release(TM) drug delivery platform technology to build and advance a pipeline of pharmaceutical products. Cingulate Inc is based in KANSAS CITY, Kan.

Read More

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with's FREE daily email newsletter.